Sugi Predict

Sugi Predict / Compounds / SCHEMBL19207565

SCHEMBL19207565

SCHEMBL19207565

CCOC(=O)CCCc1c([N+](=O)[O-])cnn1C

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ TNF P01375 2/20 0.45
▸ KDM4E B2RXH2 1/20 0.44
▸ MAPT P10636 1/20 0.44
▸ ALDH1A1 P00352 4/20 0.43
▸ TDP1 Q9NUW8 3/20 0.43
▸ KMT2A Q03164 3/20 0.39
▸ MEN1 O00255 2/20 0.39
▸ MITF O75030 1/20 0.38
▸ GAA P10253 1/20 0.38
▸ CYP3A4 P08684 1/20 0.37
▸ CYP2C9 P11712 1/20 0.37
▸ MAPK1 P28482 1/20 0.37
▸ LMNA P02545 1/20 0.37
▸ GRIK1 P39086 1/20 0.37
▸ GRIK2 Q13002 1/20 0.37
▸ GRIK3 Q13003 1/20 0.37
▸ GRIK4 Q16099 1/20 0.37
▸ GRIK5 Q16478 1/20 0.37
▸ RAB9A P51151 1/20 0.37
▸ SMN1; SMN2 Q16637 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19207668 0.79 CYP1A2 (0.42) TNFALDH1A1CYP3A4CYP2C9LMNA
SCHEMBL19207586 0.76 TNF (0.48) TNFKDM4EMAPTALDH1A1TDP1
SCHEMBL7457873 0.73 ALDH1A1 (0.54) KDM4EMAPTALDH1A1TDP1KMT2A
SCHEMBL15608878 0.73 TDP1 (0.45) KDM4ETDP1KMT2AMEN1GAA
SCHEMBL21824193 0.72 ALDH1A1 (0.44) TNFKDM4EMAPTALDH1A1TDP1
SCHEMBL25637706 0.72 ALDH1A1 (0.45) TNFKDM4EMAPTALDH1A1TDP1
SCHEMBL4656878 0.72 CYP4F2 (0.59) TNFKDM4EMAPTALDH1A1TDP1
SCHEMBL16962473 0.72 MEN1 (0.36) KDM4EMAPTTDP1KMT2AMEN1
SCHEMBL13764827 0.72 GAA (0.45) KDM4EALDH1A1TDP1KMT2AMEN1
SCHEMBL5410258 0.71 GAA (0.48) KDM4ETDP1KMT2AMEN1GAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250388601-A1 Compounds, Compositions and Methods DENALI THERAPEUTICS INC. (US) 2025-12-25 — — US disclosed
US-12358928-B2 Compounds, compositions and methods DENALI THERAPEUTICS INC. (US) 2025-07-15 — — US disclosed
US-20240150376-A1 Compounds, Compositions and Methods DENALI THERAPEUTICS INC. (US) 2024-05-09 — — US disclosed
US-20230043400-A1 Compounds, Compositions and Methods DENALI THERAPEUTICS INC. (US) 2023-02-09 — — US disclosed
CN-114437105-A Inhibitors of receptor interacting protein kinase 1 戴纳立制药公司 2022-05-06 — — CN disclosed
CN-109071504-B Inhibitors of receptor interacting protein kinase 1 戴纳立制药公司 2022-03-08 — — CN disclosed
US-20200317691-A1 Compounds, Compositions and Methods DENALI THERAPEUTICS INC. (US) 2020-10-08 — — US disclosed
US-10604535-B2 Compounds, compositions and methods DENALI THERAPEUTICS INC. (US) 2020-03-31 — — US disclosed
US-20190112318-A1 COMPOUNDS, COMPOSITIONS AND METHODS DENALI THERAPEUTICS INC. 2019-04-18 — — US disclosed
EP-3414239-A2 INHIBITORS OF RECEPTOR-INTERACTING PROTEIN KINASE 1 Denali Therapeutics Inc. (US) 2018-12-19 — — EP disclosed
US-20180022759-A1 COMPOUNDS, COMPOSITIONS AND METHODS DENALI THERAPEUTICS INC. 2018-01-25 — — US disclosed
US-20180022759-A1 COMPOUNDS, COMPOSITIONS AND METHODS DENALI THERAPEUTICS INC. 2018-01-25 — — US disclosed
US-9815850-B2 Compounds, compositions and methods DENALI THERAPEUTICS INC. (US) 2017-11-14 — — US disclosed
US-9815850-B2 Compounds, compositions and methods DENALI THERAPEUTICS INC. (US) 2017-11-14 — — US disclosed
US-9815850-B2 Compounds, compositions and methods DENALI THERAPEUTICS INC. (US) 2017-11-14 — — US disclosed
WO-2017136727-A2 COMPOUNDS, COMPOSITIONS AND METHODS DENALI THERAPEUTICS INC. (US) 2017-08-10 — — WO disclosed
WO-2017136727-A2 COMPOUNDS, COMPOSITIONS AND METHODS DENALI THERAPEUTICS INC. (US) 2017-08-10 — — WO disclosed
US-20170226127-A1 COMPOUNDS, COMPOSITIONS AND METHODS DENALI THERAPEUTICS INC. 2017-08-10 — — US disclosed
US-20170226127-A1 COMPOUNDS, COMPOSITIONS AND METHODS DENALI THERAPEUTICS INC. 2017-08-10 — — US disclosed
US-20170226127-A1 COMPOUNDS, COMPOSITIONS AND METHODS DENALI THERAPEUTICS INC. 2017-08-10 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250388601-A1 Compounds, Compositions and Methods AURKC, WEE2, ERBB2 TNF 4662/4885KDM4E 2322/4885MAPT 1905/4885
US-20200317691-A1 Compounds, Compositions and Methods PIK3CA, PLK1, PIK3CB TNF 3965/4885KDM4E 1466/4885MAPT 1843/4885
US-20240150376-A1 Compounds, Compositions and Methods PIK3CA, PLK1, PIK3CB TNF 3965/4885KDM4E 1466/4885MAPT 1843/4885
US-12358928-B2 Compounds, compositions and methods PIK3CA, PLK1, PIK3CB TNF 3965/4885KDM4E 1466/4885MAPT 1843/4885
US-20230043400-A1 Compounds, Compositions and Methods PIK3CA, PLK1, PIK3CB TNF 3965/4885KDM4E 1466/4885MAPT 1843/4885
US-20180022759-A1 COMPOUNDS, COMPOSITIONS AND METHODS PIK3CA, PLK1, PIK3CB TNF 3965/4885KDM4E 1466/4885MAPT 1843/4885
US-20170226127-A1 COMPOUNDS, COMPOSITIONS AND METHODS PIK3CA, PLK1, PIK3CB TNF 3965/4885KDM4E 1466/4885MAPT 1843/4885
US-10604535-B2 Compounds, compositions and methods PIK3CA, PLK1, PIK3CB TNF 3965/4885KDM4E 1466/4885MAPT 1843/4885
US-20190112318-A1 COMPOUNDS, COMPOSITIONS AND METHODS PIK3CA, PLK1, PIK3CB TNF 3965/4885KDM4E 1466/4885MAPT 1843/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.